Cerebrolysin for vascular dementia
1Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.
Insights
Cerebrolysin may improve cognitive and global function in vascular dementia patients. However, more research is needed due to limited trials and short follow-up periods for routine treatment recommendations.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Vascular dementia is a prevalent neurological disorder lacking definitive treatments.
- Cerebrolysin shows potential for neurotrophic and pro-cognitive effects, but existing studies have inconsistent findings.
Purpose of the Study:
- To evaluate the efficacy and safety of Cerebrolysin for treating vascular dementia.
- To synthesize evidence from randomized controlled trials on Cerebrolysin's impact on cognitive and global function.
Main Methods:
- A systematic search of the ALOIS database was conducted for randomized controlled trials (RCTs) of Cerebrolysin in vascular dementia.
- Six RCTs involving 597 participants were included after independent selection and quality assessment by two authors.
- Data extraction and meta-analysis were performed to assess treatment effects and adverse events.
Main Results:
- Meta-analyses indicated beneficial effects of Cerebrolysin on general cognitive function (MMSE, ADAS-cog+) and global clinical function (response rates).
- No significant difference in the occurrence of non-serious adverse events was observed between Cerebrolysin and control groups.
- The observed effects suggest potential benefits for patients with mild to moderate vascular dementia.
Conclusions:
- Cerebrolysin may positively influence cognitive and global function in mild to moderate vascular dementia.
- Insufficient evidence currently supports Cerebrolysin's routine use due to limited trials, variable treatment durations, and short follow-up periods.
- Further high-quality, long-term studies are warranted to establish Cerebrolysin's role in vascular dementia management.
Background:
Vascular dementia is a common disorder without definitive treatments. Cerebrolysin seems to be a promising intervention based on its potential neurotrophic and pro-cognitive effects, but studies of its efficacy have yielded inconsistent results.
Objectives:
To assess the efficacy and safety of Cerebrolysin for vascular dementia.
Search Methods:
We searched ALOIS - the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 4 November 2012 using the terms: Cerebrolysin, Cere, FPF1070, FPF-1070. ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases, numerous trial registries and grey literature sources.
Selection Criteria:
All randomized controlled trials of Cerebrolysin for treating vascular dementia without language restriction.
Data Collection And Analysis:
Two authors independently selected trials and evaluated the methodological quality, then extracted and analysed data from the included trials.
Main Results:
Six randomized controlled trials with a total of 597 participants were eligible. The meta-analyses revealed a beneficial effect of Cerebrolysin on general cognitive function measured by mini-mental state examination (MMSE) (weighted mean difference (WMD) 1.10; 95% confidence interval (CI) 0.37 to 1.82) or Alzheimer's Disease Assessment Scale Cognitive Subpart, extended version (ADAS-cog+) (WMD -4.01; 95% CI -5.36 to -2.66). It also improved patients' global clinical function evaluated by the response rates (relative risk (RR) 2.71, 95% CI 1.83 to 4.00). Only non-serious adverse events were observed in the included trials, and there was no significant difference in occurrence of non-serious side effects between groups (RR 0.97, 95% CI 0.49 to 1.94).
Authors' Conclusions:
Cerebrolysin may have positive effects on cognitive function and global function in elderly patients with vascular dementia of mild to moderate severity, but there is still insufficient evidence to recommend Cerebrolysin as a routine treatment for vascular dementia due to the limited number of included trials, wide variety of treatment durations and short-term follow-up in most of the trials.
More Related Videos
06:24Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo
Published on: July 8, 2025
05:12A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
Published on: November 22, 2024
Related Concept Videos
Alzheimer's Disease: Treatment
Cerebral Edema ll: Pathophysiology
Dementia l: Introduction
Cerebral Edema l: Introduction
Hemorrhagic Stroke l: Introduction
Ischemic Stroke l: Introduction
